Skip to main content
Clinical Trials/KCT0006322
KCT0006322
Not yet recruiting
未知

The prospective non-randomized case-control study to elucidate optimal target population of immunotherapy from real-world lung cancer patients

Samsung Medical Center0 sites800 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Diseases of the respiratory system
Sponsor
Samsung Medical Center
Enrollment
800
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Immunotherapy group
  • ? Male and female patients must be at least 19 years of age.
  • ? Patients with histologically confirmed NSCLC
  • ? Patients on palliative therapy for recurrence after surgery or de novo advanced and metastatic disease
  • ? Patients receiving reimbursed immunotherapy as a second\-line therapy (in case of targeted therapy, patients receiving immunotherapy after targeted therapy\-platinum\-based chemotherapy)
  • ? Patients who provided written informed consent for the study (including the secondary use of the study data and sharing with third parties)

Exclusion Criteria

  • 1\. Immunochemotherapy group
  • ? Patients receiving immunotherapy without reimbursement
  • ? Patients who do not provide consent to the study
  • 2\. Cytotoxic chemotherapy group
  • ? Patients receiving cytotoxic chemotherapy without reimbursement
  • ? Patients who do not provide consent to the study

Outcomes

Primary Outcomes

Not specified

Similar Trials